Business Context and Reporting Period
This Form 8-K is a current report filed by Adherex Technologies Inc. (referred to in metadata as Fennec Pharmaceuticals Inc.) on November 15, 2013. The filing details a material definitive agreement involving a private placement of equity securities and shareholder approvals obtained on November 14, 2013.
Key Financial Metrics and Capital Structure
- Offering Size: Up to 4.0 million units for gross proceeds of up to $1.6 million.
- Unit Price: $0.40 per unit.
- Unit Composition: One common share and one common share purchase warrant.
- Warrant Terms: Exercise price of $0.50 per share; exercisable for five years from issuance.
- Tranche Structure:
- First Closing: Anticipated gross proceeds of $1.354 million (expected on or about November 22, 2013).
- Second Closing: Anticipated gross proceeds of $246,000 (expected within two business days of TSX confirmation).
- Use of Proceeds: General working capital purposes.
- Shareholder Approval: 51.4% of issued and outstanding common shares approved the offering via written consent.
Note: The filing text does not provide specific values for revenue, profit, cash flow, margins, or existing debt levels. It references a press release (Exhibit 99.1) for Q3 2013 financial results, but the data is not included in this document.
Material Changes and Corporate Actions
The filing announces a significant capital raise and several proposed corporate governance changes contingent on regulatory approval and shareholder votes at the next Annual Meeting (expected prior to June 30, 2014):
- Board Representation: The Company agreed to nominate up to two directors designated by Manchester Explorer, L.P. to the board of directors.
- Warrant Exchange: Proposal to exchange outstanding warrants (issued in 2010 and 2011) for new unlisted warrants on a 1-for-10 basis with an exercise price of $0.50.
- Stock Consolidation: Proposal to consolidate common shares on a one-for-up-to-ten basis.
- Company Name Change: Proposal to change the Company's name to be determined by the board.
- Pre-emptive Rights: Manchester Explorer has the right to subscribe to future equity financings to maintain its percentage ownership.
Guidance, Risks, and Contingencies
- Regulatory Approvals: The closing of the offering is subject to receipt of applicable regulatory approvals, including approval from the Toronto Stock Exchange (TSX).
- Shareholder Vote: The warrant exchange, stock consolidation, board nominations, and name change are subject to approval at the next Annual Meeting.
- Investor Support: 683 Capital and Southpoint Capital Advisors LP have agreed to vote in favor of the Annual Meeting proposals and exchange their outstanding warrants.
- Unregistered Securities: The securities sold in this private placement are not registered under the Securities Act of 1933 and may not be offered or sold in the United States absent registration or an applicable exemption.
Investor Verification Checklist
- Verify the final closing date and actual gross proceeds received for both tranches.
- Confirm receipt of TSX approval for the offering and the proposed stock consolidation.
- Review the full text of the Q3 2013 financial results press release (Exhibit 99.1) for revenue and cash position data not included in this 8-K.
- Monitor the outcome of the Annual Meeting regarding the warrant exchange ratio and the election of Manchester's nominees.
- Confirm the final determination of the new company name.